ArticleBMC pregnancy and childbirth2026
Maternal serum adropin as a potential biomarker for placenta accreta spectrum: a cross-sectional study.
Article in BMC pregnancy and childbirth, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAdropin is a regulatory peptide implicated in endothelial homeostasis, and reduced circulating levels have been linked to endothelial dysfunction and impaired vascular remodeling. This study aimed to compare maternal serum adropin levels in pregnancies complicated by placenta previa and/or placenta accreta spectrum (PAS) with those of healthy pregnant women and to evaluate the discriminative performance of adropin for abnormal placental invasion.
methodsThis cross-sectional study included 84 singleton pregnancies at ≥ 34 weeks of gestation: 42 women diagnosed with placenta previa and/or PAS and 42 healthy pregnant women who underwent cesarean delivery. Maternal preoperative serum adropin concentrations were quantified using a commercially available enzyme-linked immunosorbent assay (ELISA). Demographic, obstetric, ultrasonographic, and intraoperative findings were recorded. Receiver operating characteristic (ROC) curve analysis was performed to assess the discriminative ability of serum adropin levels for abnormal placental invasion.
resultsA total of 84 pregnant women were included in the study: 42 healthy controls, 30 patients with placenta previa without PAS, and 12 patients diagnosed with PAS. Maternal serum adropin concentrations were significantly reduced in pregnancies complicated by placenta previa and/or PAS compared with healthy controls (p < 0.001). No significant differences were observed between groups in terms of body mass index or routine laboratory parameters. ROC analysis demonstrated moderate discriminative performance, with an area under the curve of 0.778 (p < 0.001). An adropin cut-off value of ≤431.27 pg/mL yielded a sensitivity of 71.4% and a specificity of 78.6%.
conclusionMaternal serum adropin levels are significantly reduced in pregnancies complicated by placenta previa and/or PAS. Decreased adropin concentrations may reflect a disturbed metabolic-endothelial milieu associated with abnormal placental invasion. Adropin may serve as a supportive biomarker; however, findings should be interpreted cautiously given the cross-sectional design. Further prospective studies are required to clarify its potential clinical utility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.